42 results about "Targeting chemotherapy" patented technology

The present invention discloses preparation process of medicine-carrying particle containing surface transferrin for glioma targeting chemotherapy, and belongs to the field of preparing technology of medicine-carrying targeting particle. Biodegradable polymer polylactic acid, polyglycolic acid, polycaprolactone or copolymer of lactic acid and glycolic acid and chemotherapeutical medicine carmustine, Adriamycin or taxol are dissolved in acetone, acetonitrile or dimethyl sulfoxide; and the solution is emulsified in solution of transferrin or combined with transferrin chemically after co-dialysis with cholesterol modified glucosan dialdehyde to prepare the medicine-carrying polymer particle containing surface transferrin. This kind of particle may be injected into tumor cavity to make medicine released crossing blood brain barrier and targeting glioma to reach the high inside inhibition of tumor. The present invention has simple preparation process and obvious curative effect.

A system for chemotherapy delivery comprises a plurality of slots to receive a corresponding one of a plurality of cartridges; a plurality of pumps, wherein each of the plurality of pumps is configured to be connected to the corresponding one of the plurality of cartridges, and the plurality of pumps are configured to pump at least one drug contained in at least one of the plurality of cartridges to a patient according to a treatment protocol; a blood glucose sensor communicatively coupled to the plurality of pumps, and configured to measure a blood glucose level of the patient; a processor connected to the plurality of pumps and the blood glucose sensor and configured to adjust a delivery property of the at least one drug according to the measured blood glucose level of the patient.

The invention discloses a magnetic nano-targeted oxidized graphene drug carrier and a preparation method and an application method thereof. The preparation method comprises the following steps: using oxidized graphene, FeCl3.6H2O, sodium acetate and aniline monomer as raw materials, and using a chemical coprecipitation method and an in-situ synthesis method to obtain the magnetic nano-targeted oxidized graphene drug carrier; the mass ratio of the oxidized graphene, FeCl3.6H2O, sodium acetate and aniline monomer is 7-8: 23-25: 47-49: 0.5-1.5. The prepared magnetic nano-targeted oxidized graphene drug carrier GO-Fe3O4-PANI is a anti-cancer novel targeted oxidized graphene drug carrier, wherein the oxidized graphene drug carrier is based on magnetic targeting and drug-carrying function, combines multiple functions of magnetic therapy, thermal therapy and chemotherapy, has good biocompatibility, water solubility and stability, has magnetic targeting property and thermal therapy effect, and has photo-thermal therapy, targeted chemotherapy and other multifunctional multi-dimensional cancer treatment effects loaded with anti-tumor drugs.

The invention relates to dialkyltriazene-bearing estrogens and anti-estrogens that are suited for use as chemotherapeutic drugs for treating carcinomas of the sexual organs of humans and animals.

The invention relates to a medical use of engrafted nanometer carbon for preparing the target medicine for lymph labeling or directly killing transferred cancer cell in the lymph gland. The engrafted nanometer carbon is produced by surface modification, connecting nanometer carbon with hydrophilic group. The engrafted nanometer carbon can be dispersed into engrafted nanometer carbon suspension in water without dispersing auxiliary and grinding scattering. The suspension has a better lymph labeling and lymph target treatment effect, and has more surface active group and connects to other chemotherapy medicine. Therefore, it is possible to exploit the engrafted nanometer carbon to the lymph target chemotherapy medicine.

The present technology provides methods of identifying tumor cells that are resistant to one or more chemotherapy agents, as well as preventing or reducing such resistance in cancer, and predicting survivability of a subject having cancer.

The present invention relates to a magnetic nanoparticle for tumor therapy, comprising: a magnetic core; a shell encapsulating a surface of the magnetic core, wherein the shell is made of a polymer with carboxylic groups; a poly-nucleotide chain connected to a surface of the shell; an anti-tumor drug connected to the poly-nucleotide chain, wherein the anti-tumor drug comprises at least one functional group, and each of the functional group is independently a pyrimidine group or a purine group; and an antibody connected to the shell, wherein the antibody identifies a target tumor. In addition, the present invention further provides a method for manufacturing the magnetic nanoparticles for tumor therapy and a pharmaceutical composition containing the magnetic nanoparticles. Accordingly, the magnetic nanoparticle for tumor therapy of the present invention can achieve effective treatment of tumor by synergistic effects between hyperthermia and targeted chemotherapy.

The invention discloses a cancer gene detection kit based on a second-generation sequencing probe capture method. The cancer gene detection kit comprises quality control materials, library building reagents and an RNA probe; quality control materials: a negative quality control material and a positive quality control material; library building reagents: a tail end repairing and A adding reagent, ajoint adding reagent, an amplification reagent, a hybridization reagent, a capture reagent and an amplification reagent; the RNA probe is a probe panel; the synthesis type of the RNA probe is an RNAsingle strand; the length interval is 90-120 nt; and biotin is marked. The cancer gene detection kit in the invention aims at patients with lung cancer, colorectal cancer, breast cancer and ovarian cancer. Detection of 18 genes panel is carried out; the receptivity of medicines, such as targeting and chemotherapy, on a patient is comprehensively interpreted from the gene level; according to the difference of individual gene levels, an accurate personalized treatment scheme is made; immune medication treatment is guided; the sensitivity and toxic and side effects of chemotherapy drugs are predicted; a medication prognosis condition is dynamically monitored, etc.

A rapid, infrared spectroscopic method has been developed to assess the efficacy of targeted chemotherapeutics against the structure of the polypeptide target, based on the effect of natural polymorphic sequence variation on the conformation of the protein. This method has an advantage over the current genomics-based screening, as the new method provides a direct readout of the structural, and hence functional, outcome of polymorphisms to the protein region targeted by drugs. It allows rapid measurement of a protein's susceptibility to therapeutic targeted agents, prior to using the drug as treatment in the patient. This method can be used to identify biomarkers for a response for a protein to a drug which can be readily tested, interpreted, and used in a clinical setting.

Disclosed are compound for targeting chemotherapeutic agents to mammalian mitochondria. Also disclosed are monoamine oxidase-specific compositions, and methods of using them for the selective therapy of mammalian cancers, and in particular, in the treatment of human gliomas. Also disclosed are methods employing the novel targeted chemotherapeutics with one or more conventional anti-cancer therapies, including, for example, radiotherapy, or multi-drug regimens.

The present invention provides a method of peptide histochemical diagnosis to detect the peptide binding protein in the cancer tissue. This peptide binding specifically to tumor cells is linked to the dextran coated iron oxide nanoparticle. The peptide linked dextran coated iron oxide nanoparticle can be used to bind to the formalin-fixed and paraffin-embedded tumor surgical specimens, and the method of present invention can be used to evaluate the efficacy of peptide-targeted chemotherapy for treatment of cancer patients.

The invention discloses a series of affinity polypeptides YQC-1 and YQC-2 related to a coxsackie adenovirus receptor. The polypeptides possibly realize near-infrared imaging of specific malignant tumors due to the property of specific binding of the coxsackie adenovirus receptor, can be used for preparation of drugs for cell adhesion inhibition, diagnosis or tracing of tumors and targeted chemotherapy and used for pharmaceutical necessities or attachments, so that the aim of nondestructively monitoring early malignant tumors in situ in real time is achieved. The invention relates to the field of drugs related to tumor diagnosis, and in particular to multiple polypeptides, affinity tests of the polypeptides, pharmaceutical compositions taking the polypeptides as active ingredients, and application of the polypeptides in preparation of diagnostic drugs.

The invention provides a compound thermo-sensitive liposome containing a CT contrast agent and tumor chemotherapy medicaments, and a method for preparing the compound thermo-sensitive liposome. The novel compound thermo-sensitive liposome provided by the invention can be applied to thermal targeted chemotherapy, particularly thermal targeted chemotherapy at CT measurement and control temperature, can make the temperature control of thermal therapy more accurate, greatly reduce the side effect of the thermal therapy and the thermal injury to normal tissues, and improve the effect of the thermal therapy; meanwhile, the synchronous thermal targeted chemotherapy obviously enhances the effect of the thermal therapy and reduces the toxic and side effects of systemic chemotherapy; therefore, the compound thermo-sensitive liposomes has good social benefit.

The invention discloses a composite prodrug nanocarrier for reversing tumor drug resistance and a preparation method thereof, and belongs to the field of polymer materials and medical engineering. Thecomposite prodrug nanocarrier is formed by self-assembly of an amphiphilic pH-sensitive macromolecular prodrug and a superparamagnetic nanoparticle, and has a typical core-shell structure, the core of the composite prodrug nanocarrier is formed by coating a drug-coupled hydrophobic segment of an amphiphilic pH-sensitive macromolecular prodrug with the superparamagnetic nanoparticle, and the shellis formed by a hydrophilic segment of an amphiphilic pH-sensitive macromolecular prodrug. Since the composite prodrug nanocarrier uses the conditional responsive amphiphilic macromolecular prodrugtoreplace a conditional responsive amphiphilic macromolecule, the composite nanocarrier simultaneously has both efficient magnetic hyperthermia and targeted chemotherapy interference-free from magnetocaloric action, the magnetic hyperthermia and chemotherapy can be more effectively combined and targeted to tumor tissues, and effective reversal of tumor drug resistance can be ultimately achieved.

The invention relates to a dextran-MLDH-fluorouracil supermolecular assembly magnetic targeting sustained release tablet, the sustained release tablet takes dextran-MLDH-fluorouracil DMF as the drug storage and transmission system, and hydrophilic gel auxiliary material as the skeletal material, and the tablet is prepared by direct powder compression. The sustained release tablet has typical in-vitro control release ability, a special and durable in-vivo drug process and prominent magnetic target specificity. Preparation of the DMF magnetic target control release drug delivery system is realized for the first time, a DMF magnetic matrix tablet is prepared by combination of conventional auxiliary materials and DMF, which is a novel inorganic nano drug carrying system, therefore oral medication and magnetic target chemotherapy of fluorouracil, which is a wide-spectrum anti-cancer drug, are provided with a realization way. The dextran-MLDH-fluorouracil supermolecular assembly magnetic targeting sustained release tablet is suitable for the preparation production of magnetic drug control release tablets, which take magnetic layered double hydroxide(MLDH) as the carrier, has the processing advantages of low cost and simple technology, and has the characteristics of integration of magnetic-target and control-release functions, convenient drug delivery, durable effect, stable curative effect, and little toxic and side effects.

The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing HER2-neu and/or EGFR expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the probable sensitivity of a patient s tumor to treatment with receptor tyrosine kinase targeted chemotherapy by examination of the amount of HER2-neu and/or EGFR mRNA in a patient s tumor cells and comparing it to a predetermined threshold expression level for those genes. More specifically, the invention provides to oligonucleotide primer pairs EGFR and HER2-neu and methods comprising their use for detecting levels of EGFR and HER2-neumRNA, respectively.

The invention discloses a preparation method of fluorouracil targeted slow release drugs based on ganoderma spores, and belongs to the technical field of drug carriers and slow release. The preparation method of the fluorouracil targeted slow release drugs based on the ganoderma spores includes the steps: firstly, pretreating natural ganoderma spores to obtain a natural nontoxic internally and externally through ganoderma spore carrier with good biocompatibility; secondly, synthesizing Fe3O4 nanoparticles on the surfaces of the ganoderma spores and inside the ganoderma spores by a chemical coprecipitation method to magnetize the ganoderma spores; thirdly, combining the ganoderma spores with fluorouracil serving as a broad-spectrum anti-tumor drug by the aid of a vacuum loading technique. The preparation method can be used for preparing the fluorouracil oral targeted drugs. The fluorouracil drugs are positioned in a diseased region under the action of an external magnetic field and released, adverse drug reaction is reduced, administration frequency is decreased, maximum drug therapeutic effects are achieved, and a new approach is provided for oral medication and magnetic targeted chemotherapy.